PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 28, 2026Pediatrics International0 citations

Denosumab in Aggressive Benign Bone Lesions in Children

View Full Paper
TMTatiana MoreiraSCSalomé CavaleiroDADaniela Alves

Key Points

  • The aim is to assess the effectiveness of denosumab in treating aggressive benign bone lesions in children.
  • Data from clinical cases analyzed for the treatment of aggressive benign bone lesions.
  • Denosumab administered as a therapeutic intervention with follow-up evaluations for outcomes.
  • No specific numerical results or findings provided in the abstract.

Abstract

The authors have nothing to report. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Moreira et al. (2026) studied this question.

synapsesocial.com/papers/6a17dc063fad632b0f9d8bfchttps://doi.org/10.1111/ped.70415
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls2020 · 110 citations
  2. 2Denosumab: an Emerging Therapy in Pediatric Bone Disorders2017 · 147 citations
  3. 3Safety and efficacy of denosumab for adults and skeletally mature adolescents with giant cell tumour of bone: interim analysis of an open-label, parallel-group, phase 2 study2013 · 588 citations
  4. 4OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis1999 · 3,368 citations
  5. 5Denosumab: a potential new and innovative treatment option for aneurysmal bone cysts2013 · 184 citations